ArticleCurrent oncology (Toronto, Ont.)2025
Patient Experiences Regarding Feasibility of Implementing Real-World EQ-5D Collection at an Oncology Centre in Ontario, Canada.
Article in Current oncology (Toronto, Ont.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Examining the Association Between Equity-Related Factors and EQ-5D-3L Health Utilities of Patients with Cancer.Current oncology (Toronto, Ont.) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Cancer treatments impact health-related quality of life (HRQoL). EQ-5D is a standardized generic measure of HRQoL. The objective of this project was to assess, from the patient's perspective, the feasibility of implementing real-world EQ-5D-3L measurement at a pilot site, as a first step to large-scale collection of EQ-5D from patients with cancer across Ontario. This was a prospective longitudinal study at a single oncology centre to understand the feasibility of routinely collecting EQ-5D-3L while patients receive chemotherapy (N = 170). Consenting patients completed an additional questionnaire on feasibility, and a subset of participants were directly interviewed to provide further feedback and suggest improvements to questionnaire collection. Themes emerging from the interviews were analyzed using content analysis. Of 170 eligible and consenting patients who completed an initial EQ-5D-3L questionnaire, 103 (60.6%) completed at least one follow-up questionnaire. When asked about willingness to answer future questionnaires at subsequent visits, 115 (67.3%) answered definitely; 35 (20.5%) very likely. Patients provided feedback on their overall experience of completing EQ-5D-3L, the questionnaire presentation, frequency of completion, and analytic plans. Patients expressed that routinely collecting EQ-5D-3L is feasible. Incorporating patient feedback regarding EQ-5D collection will facilitate implementation of systematic collection at cancer centres across Ontario.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.